Securities Class Action Reminder (NASDAQ

VTRS): Kessler Topaz Meltzer & Check, LLP Reminds Viatris Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Pennsylvania against Viatris Inc. (“Viatris”) (NASDAQ:VTRS). The action charges Viatris with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of Viatris’s materially misleading statements and omissions to the public, Viatris’s investors have suffered significant losses.

CLICK HERE TO SUBMIT YOUR VIATRIS LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/viatris-inc?utm_source=PR&utm_mediu ...

LEAD PLAINTIFF DEADLINE: JULY 14, 2023

CLASS PERIOD: MARCH 1, 2021 THROUGH FEBRUARY 25, 2022

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Jonathan Naji, Esq. at [phone] or via email at [e-mail]

Kessler Topaz is one of the world’s foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

VIATRIS’S ALLEGED MISCONDUCT

At the outset of the Class Period, Viatris announced a multi-phase plan, the first phase of which that would allow it to: (1) create a stable revenue base; (2) realize $1 billion in cost synergies by 2024; and (3) improve cash conversion and free cash flow generation. Defendants claimed that Viatris would achieve its first phase goals through its strong pipeline of new products, including those in its biosimilars business. Defendants further represented that Viatris’s strong pipeline and business development would offset erosion of the company’s base business.

However, contrary to Defendants representations, the company was experiencing significantly more competition in its United States complex generics business than disclosed. As a result, the company was not able to effectively manage its base business erosion or create a stable revenue base. Instead, throughout 2021, Viatris total revenues were declining quarter-over-quarter.